Analysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) Price Target at $40.13

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $40.13.

A number of brokerages recently commented on BCYC. Royal Bank of Canada restated an "outperform" rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. B. Riley downgraded shares of Bicycle Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $33.00 to $28.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. HC Wainwright reiterated a "buy" rating and set a $55.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, JMP Securities restated a "market outperform" rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th.

Bicycle Therapeutics Stock Down 0.1 %

Shares of Bicycle Therapeutics stock traded down $0.02 on Thursday, hitting $20.35. 725,910 shares of the company's stock traded hands, compared to its average volume of 360,832. The firm's 50-day moving average is $24.23 and its 200 day moving average is $23.08. The stock has a market cap of $967.40 million, a P/E ratio of -6.11 and a beta of 0.89. Bicycle Therapeutics has a 52-week low of $13.31 and a 52-week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company's revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.26) earnings per share. Equities research analysts forecast that Bicycle Therapeutics will post -3.07 EPS for the current year.

Insider Activity at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 6,256 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the sale, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kevin Lee sold 3,212 shares of the company's stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the sale, the chief executive officer now directly owns 380,864 shares of the company's stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,840 shares of company stock valued at $259,128. Insiders own 8.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Assetmark Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth $34,000. GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company's stock valued at $46,000 after acquiring an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 69.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company's stock valued at $162,000 after acquiring an additional 2,918 shares during the period. XTX Topco Ltd bought a new position in Bicycle Therapeutics during the second quarter worth about $206,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in Bicycle Therapeutics during the third quarter valued at approximately $257,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.